112 studies found for:    "Intraocular melanoma"
Show Display Options
Rank Status Study
1 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
2 Terminated Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Liver Metastases;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: ipilimumab;   Radiation: yttrium Y 90 glass microspheres;   Other: laboratory biomarker analysis
3 Completed
Has Results
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: Cixutumumab;   Other: Laboratory biomarker analysis
4 Terminated
Has Results
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Stage IIA Uveal Melanoma;   Stage IIB Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma
Interventions: Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
5 Recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
6 Completed
Has Results
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: sorafenib tosylate
7 Active, not recruiting Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Drug: dacarbazine;   Other: laboratory biomarker analysis
8 Terminated Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Extraocular Extension Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis
9 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
10 Unknown  Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
11 Terminated Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
Conditions: Intraocular Melanoma;   Metastatic Cancer
Interventions: Drug: fotemustine;   Drug: isolated perfusion
12 Completed
Has Results
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Condition: Intraocular Melanoma
Intervention: Drug: nab-paclitaxel
13 Recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
14 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
15 Completed Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Genetic: fluorescence in situ hybridization;   Other: laboratory biomarker analysis;   Procedure: fine-needle aspiration;   Procedure: therapeutic conventional surgery;   Other: Questionnaires
16 Recruiting A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: LXS196
17 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
18 Completed New Biopsy Technique for Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
19 Not yet recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib
20 Recruiting Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Drug: AEB071

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years